October 10, 2011
Ono Pharmaceutical announced on September 26 that it received marketing approval on the same day for the selective NK1 receptor antagonist Proemend IV Infusion 150 mg (fosaprepitant meglumine) for the treatment of chemotherapy-induced nausea and vomiting (CINV). A prodrug of...read more